BTIG downgraded CareDx (NASDAQ:CDNA) to “neutral” from “buy” and removed its price target. The stock closed at $8.59 on May 10. CareDx is a market leader in blood-based testing for both heart and kidney transplant...
BTIG initiated coverage of Sophia Genetics (NASDAQ:SOPH) with a “buy” rating and $6 price target. The stock price closed at $2.06 on Dec. 30. Sophia is a rapidly growing, global healthcare technology company that sells...
BTIG analyst Mark Massaro assumed coverage of Bionano Genomics (NASDAQ:BNGO) with a “buy” rating and price target of $3.50. The stock closed at $2.16 on Dec. 9. Bionano provides optical genome mapping technology tools...
BTIG launched coverage of Akoya Biosciences (NASDAQ:AKYA) with a “buy” rating and $16 price target. The stock closed at $9.29 on June 21. Akoya is a rapidly growing life sciences technology company that offers a...
BTIG downgraded Talis Biomedical (NASDAQ:TLIS) to “sell” from “neutral” with a price target of $1, citing a delay in the beta-phase rollout of the Talis One COVID-19 diagnostic, which was planned for the first quarter...
BTIG launched coverage of MDx Health (NASDAQ:MDXH) with a “buy” rating and price target of $15. The stock closed at $9.04 on Nov. 26. MDx Health is a precision diagnostics company that offers a portfolio of...
Analysts for BTIG and Canaccord Genuity launched coverage of Lucid Diagnostics (NASDAQ:LUCD) with “buy” ratings and price targets of $14 and $18, respectively. The stock closed at $9.52 on Oct. 5. Lucid recently...
BTIG downgraded Talis Biomedical (NASDAQ:TLIS) to “neutral” from “buy” and removed its price target after president, CEO, director and co-founder, Brian Coe, stepped down from the board and executive. The stock closed...
BTIG initiated coverage of point-of-care diagnostics company, Talis Biomedical, (NASDAQ:TLIS) with a “buy” rating and $18 price target. The stock closed at $12.95 on March 8. “Consistent with our checks with KOLs … we...
BTIG raised its price target for OncoCyte (NYSE American:OCX) to $8 from $5, citing a recent direct offering of $25-million with its two largest institutional shareholders, which gives the company “ammunition to execute...